secwatch.observer — SEC 8-K summary
======================================

Issuer:     Claritev Corp (CTEV)
CIK:        0001793229
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001793229-24-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MultiPlan Q4 rev $244.1M, net loss $31.4M; guides FY24 rev $1.0B-$1.03B
-----------------------------------------------------------------------

- Q4 2023 revenue $244.1M (+1.3% YoY), net loss $31.4M (vs $650.1M loss), adjusted EBITDA $156.8M.
- Full year 2023 revenue $961.5M (-10.9%), net loss $91.7M (vs $572.9M loss), adjusted EBITDA $618.0M.
- FY 2024 guidance: revenue $1,000M-$1,030M, EBITDA $630M-$650M; Q1 2024 revenue $235M-$250M.
- Identified $22.9B potential medical cost savings in 2023; acquired Benefits Science for $140.9M; repurchased $165.8M debt.
- CEO Dale White to be succeeded by Travis Dalton; White highlights progress on growth plan and debt reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1793229/000179322924000010/0001793229-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1793229/000179322924000010/mpln-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001793229-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer